This segment focuses on the research, development, and commercialization of therapies for ocular diseases, including diabetic retinopathy and glaucoma. Aerpio's lead product candidate, razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP), is a key asset in this area. R&D efforts involve clinical trials to assess the efficacy and safety of razuprotafib in treating non-proliferative diabetic retinopathy and open-angle glaucoma/ocular hypertension. The company aims to improve patient outcomes by developing targeted treatments that address the underlying causes of vision loss and vascular instability in the eye. Future opportunities include expanding the application of Tie2 activation technology to other ocular conditions and exploring combination therapies for enhanced efficacy.

This segment is dedicated to developing compounds that promote vascular stabilization, addressing conditions where blood vessel integrity is compromised. Aerpio's approach centers on activating Tie2, a receptor tyrosine kinase crucial for maintaining vascular stability. Research and development activities include preclinical studies and clinical trials to evaluate the potential of Tie2 activators in various vascular-related diseases. The company's pipeline includes ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications like nephropathy and diabetic macular edema. By targeting Tie2, Aerpio aims to develop therapies that prevent vascular leakage, reduce inflammation, and improve tissue perfusion, ultimately benefiting patients with vascular disorders.